Microbot Medical Inc.

NASDAQ:MBOT

Medical - Instruments & Supplies

Healthcare
$0.98 -2.93%

-$0.06 today

Market cap
$65.73M
Beta
1.04
P/E (TTM)
-8.6
EPS (TTM)
-$0.21
52W Low $1.60High $4.67

Volume 0.87M

Average 1.60M

MBOT EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Microbot Medical Inc.NASDAQ: MBOT

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$3.66M, compared with -$2.59M a year earlier. Trailing-twelve-month EBITDA was -$14.17M.

Context

  • EBITDA grew in size in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 2 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -15.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$3.66M-5.9% QoQ
Last fiscal yearDec 2025
-$13.1M-15.4% YoY
LTMMar 2026
-$14.17M-22.2% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-41.5%+100.0%+141.5 pp
1 year-15.4%+100.0%+115.4 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(13.1M) USD
Year-over-year change
-15.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How MBOT compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -22.2% is the 8th highest of 10, against a peer median of -14.1%.
  • EBITDA amounts to 13493.3% of revenue for MBOT, versus a peer median of 337.0%.
MBOT Competitors
EBITDA for MBOT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$78.84M USD+1391.3%——
ZTEKZentek Ltd.LTM Mar 2026-CA$9.7M CAD-3.8%—5840.5%
MBOTMicrobot Medical Inc.LTM Mar 2026-$14.17M USD-22.2%—13493.3%
OVIDOvid Therapeutics Inc.LTM Mar 2026-$24M USD+7.8%—337.0%
VANIVivani Medical, Inc.LTM Mar 2026-$26.64M USD-14.1%——
CLNNClene Inc.LTM Mar 2026-$29.2M USD-21.6%—21792.5%
CRDLCardiol Therapeutics Inc.LTM Mar 2026-CA$36.27M CAD-16.2%——
RCELAVITA Medical, Inc.LTM Mar 2026-$37.72M USD+25.1%—52.1%
CNTXContext Therapeutics Inc.LTM Mar 2026-$40.18M USD-45.5%——
DCGODocGo Inc.LTM Mar 2026-$156.43M USD-1199.8%—51.8%
Peer median (excluding MBOT) —-14.1%—337.0%

Competitors are the stored peer set for MBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00106K91K0
Gross Profit00(106K)(91K)0
Gross Margin—————
Research & Development6.15M7.74M5.72M6.63M6.28M
Selling, General & Admin5.41M5.58M4.13M5M8.25M
Operating Expenses11.36M13.28M9.75M11.53M14.74M
Depreciation & Amortization76K102K106K91K47K
EBITDA(11.24M)(13.34M)(10.63M)(11.35M)(13.1M)
EBITDA Margin—————
Operating Income(11.36M)(13.28M)(9.86M)(11.63M)(14.74M)
Operating Margin—————
Interest Income44K54K228K182K1.29M
Interest Expense00000
Other Income / Expenses44K113K(885K)182K1.6M
Income Before Tax(11.31M)(13.17M)(10.74M)(11.44M)(13.14M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(11.31M)(13.17M)(10.74M)(11.44M)(13.14M)
Net Margin—————
EPS (Basic)(1.59)(1.81)(1.05)(0.73)(0.29)
EPS (Diluted)(1.59)(1.81)(1.05)(0.73)(0.29)
Weighted Avg Shares7.11M7.26M10.2M15.65M45.79M
Weighted Avg Shares (Diluted)7.11M7.26M10.2M15.65M45.79M

Microbot Medical Inc.

NASDAQ:MBOT

Intrinsic Alpha fair value

Locked

Current Price

$0.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.